Yixintang Pharmaceutical (SZ:002727) Xin Lang Cai Jing·2025-11-21 01:25Core Viewpoint - Yunnan Yixintang Pharmaceutical Group Co., Ltd. has experienced a decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in its business operations [2] Financing and Trading Activity - On November 20, Yixintang's stock fell by 1.26% with a trading volume of 127 million yuan. The financing buy-in amounted to 15.22 million yuan, while the financing repayment was 13.30 million yuan, resulting in a net financing buy of 1.92 million yuan. The total financing and securities balance reached 259 million yuan [1] - The current financing balance of 258 million yuan accounts for 3.31% of the circulating market value, which is above the 70th percentile of the past year, indicating a high level of financing [1] - In terms of securities lending, 300 shares were repaid and 400 shares were sold on November 20, with a selling amount of 5,324 yuan. The remaining securities lending volume is 56,500 shares, with a balance of 752,000 yuan, which is below the 50th percentile of the past year, indicating a low level of securities lending [1] Financial Performance - For the period from January to September 2025, Yixintang reported a revenue of 13 billion yuan, a year-on-year decrease of 4.33%, and a net profit attributable to shareholders of 269 million yuan, down 8.17% year-on-year [2] - Since its A-share listing, Yixintang has distributed a total of 2.02 billion yuan in dividends, with 764 million yuan distributed over the past three years [2] Shareholder Structure - As of September 30, 2025, Yixintang had 37,500 shareholders, an increase of 10.53% from the previous period. The average number of circulating shares per person decreased by 9.53% to 10,596 shares [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third-largest shareholder with 22.31 million shares, an increase of 3.74 million shares from the previous period. Several new funds have entered the top ten shareholders list, indicating a shift in institutional holdings [3]